Penumbra (Penumbra) EBIT per Share : $2.07 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Penumbra EBIT per Share?

Penumbra's EBIT per Share for the three months ended in Dec. 2023 was $0.63. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.07.

During the past 12 months, the average EBIT per Share Growth Rate of Penumbra was 1353.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Penumbra's EBIT per Share or its related term are showing as below:

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Penumbra was 41.40% per year. The lowest was -50.30% per year. And the median was 4.60% per year.

PEN's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 6.75
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Penumbra's EBIT for the three months ended in Dec. 2023 was $25 Mil.

Penumbra EBIT per Share Historical Data

The historical data trend for Penumbra's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Penumbra EBIT per Share Chart

Penumbra Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

1.31

-1.09

-0.23

0.15

2.08

Penumbra Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															0.12	0.21	0.46	0.79	0.63

Penumbra EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Penumbra's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	81.389	/	39.217
=	2.08

Penumbra's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	24.652	/	39.315
=	0.63

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.07

Penumbra (NYSE:PEN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Penumbra EBIT per Share Related Terms

Thank you for viewing the detailed overview of Penumbra's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Penumbra (Penumbra) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Penumbra Inc (NYSE:PEN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

PEN:Mexico 0P8:Germany

Address

One Penumbra Place, Alameda, CA, USA, 94502

Website

https://www.penumbrainc.com

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are primarily sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Executives

Harpreet Grewal	director	C/O VISTAPRINT USA, INCORPORATED, 100 HAYDEN AVE., LEXINGTON MA 02050
Surbhi Sarna	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Johanna Roberts	officer: EVP, Gen. Counsel & Secretary	PENUMBRA, INC., ONE PENUMBRA PLACE, ALAMEDA CA 94502
Bridget O'rourke	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Adam Elsesser	director, officer: Chairman, CEO and President	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Don W. Kassing	director	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Thomas Wilder	director	2 MUSICK, IRVINE CA 92618
Arani Bose	director, officer: Chief Innovator	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Lynn Rothman	officer: EVP and Chief Business Officer	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
James Robert Pray	officer: President, International	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Sridhar Kosaraju	officer: CFO and Head of Strategy	1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Maggie Yuen	officer: Chief Financial Officer	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Lambert Shiu	officer: Chief Accounting Officer	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Janet Leeds	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Robert D. Evans	officer: EVP, Gen. Counsel & Secretary	ONE PENUMBRA PLACE, 1351 HARBOR BAY PARKWAY, ALAMEDA CA 94502